ABSTRACT
After their discovery, H2 antagonists reached central importance in clinical practice for the treatment of peptic diseases and are now widely used. Reports of adverse effects due to this class of drugs have not been so important and frequent as for H1 antagonists. Nevertheless, because of their large use, often in long-term treatments and in some countries "over the counter," a benefit/risk ratio evaluation appears necessary.
